Latest news with #VigilNeuroscience
Yahoo
23-05-2025
- Business
- Yahoo
Sanofi buys Vigil Neuroscience for $470m in Alzheimer's push
Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company. The deal will see Sanofi acquire all outstanding common shares of US-based Vigil for $8 per share in cash at closing. Virgil's shares closed at $2.31 on 21 May, meaning Sanofi is paying a premium of 246%. Vigil has a current market cap of $107.8m. Part of the deal also includes an additional $2 cash payment per share upon the first commercial sale of Vigil's Alzheimer's asset, VG-3927. Although Vigil has two candidates in its pipeline, Sanofi's buyout centred around the potential of VG-3927. Indeed, Vigil's other programme – the fully human monoclonal antibody iluzanebart dubbed VGL101 – is not part of the acquisition and will return to its original licensor, Amgen. Sanofi has not hidden its high regard for VG-3927, with the $40m investment made in June 2024 giving the French drugmaker the exclusive right of first negotiation regarding its licensing. With the buyout of Vigil, Sanofi now has full control of VG-3927, including research, development, manufacturing, and commercialisation duties. VG-3927 is an oral small-molecule agonist of triggering receptor expressed on myeloid cells 2 (TREM2). Evidence so far suggests that activating TREM2 could enhance the neuroprotective function of microglia – the resident immune cells of the central nervous system – in Alzheimer's. Indeed, genetic factors such as rare variants of TREM2 strongly increase the risk of developing the disease. Vigil has reported positive data from a Phase I clinical trial (NCT06343636) evaluating VG-3927 in healthy volunteers. The drug demonstrated a favourable safety and tolerability profile across all cohorts – including the elderly cohort – of 115 participants. Vigil planned to advance the therapy into a Phase II trial in Q3 2025, as per an April update. Sanofi did not comment on whether the timeline will be affected by the acquisition, confirming only that it would go ahead into a Phase II clinical study. 'TREM2 represents a compelling target at the intersection of immune dysregulation and neurodegeneration, particularly in people living with Alzheimer's because they face devastating cognitive decline with limited treatment options,' said Houman Ashrafian, Sanofi's head of research and development. Currently approved therapies such as Eisai and Biogen's Leqembi (lecanamab) and Eli Lilly's Kisunla (donanemab) do not stop or reverse disease progression. While gaining approvals in multiple regions, the drugs have struggled in national coverage schemes due to questions around cost efficiency. Sanofi believes its new asset can fill this unmet need for Alzheimer's patients, along with delivering a 'safer and [more] convenient' option. 'Vigil's expertise is complementary to our capabilities in neurology and reinforces our dedication to developing innovative medicines to improve people's lives. Vigil's team are a welcome addition, and we look forward to working with them and the patient community,' Ashrafian added. Vigil is not the only pharma company developing a TREM2 candidate for Alzheimer's. Novartis is gearing up to advance its candidate VHB937 into Phase II development in H2 2025. William Blair analyst Myles Minter believes the deal price for Vigil 'is fairly valued', adding that the company would likely not have agreed to the buyout if the data for VGL101 was promising. 'For VG-3927, we see the orally administered small-molecule programme as differentiated from other TREM2 targeting treatments, and if successful, we believe it could lead to a paradigm shift in the treatment of Alzheimer's disease,' Minter added in a research note. "Sanofi buys Vigil Neuroscience for $470m in Alzheimer's push" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi
Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by Sanofi. French pharmaceutical giant Sanofi agreed to pay $8.00 per share in cash at closing, or $470 million, plus $2.00 more per share in cash if Vigil's Alzheimer's drug achieves commercial sales. Vigil's drug VG-3927 is a Phase 2-ready clinical candidate, it Neuroscience (VIGL) shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be acquired by French pharmaceutical giant Sanofi (SNY). Sanofi agreed to pay $8.00 per share in cash at closing, a significant premium over Vigil's closing price of $2.31 on Wednesday, for a total of $470 million. The company will pay an additional $2.00 per share in cash if Vigil's Alzheimer's drug, VG-3927, achieves commercial sales, which would bring the total to $600 million. The deal is expected to close in the third quarter of 2025. VG-3927 is a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease, Vigil said. U.S.-listed shares of Sanofi edged lower in recent trading Thursday. The stock is up nearly 10% in 2025 so far. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. 'We are incredibly proud of the legacy we have built at Vigil and today's announcement is a testament to the value of our TREM2 agonist pipeline,' said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. 'Sanofi's development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer's disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on VIGL: Disclaimer & DisclosureReport an Issue Vigil Neuroscience Inc trading halted, news pending Vigil Neuroscience Advances Clinical Trials and Financial Stability Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year Vigil Neuroscience sees cash runway into 2026 Vigil presents data on oral small molecule program including VG-3927 Sign in to access your portfolio
Business Insider
22-05-2025
- Business
- Business Insider
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. 'We are incredibly proud of the legacy we have built at Vigil and today's announcement is a testament to the value of our TREM2 agonist pipeline,' said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. 'Sanofi's development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer's disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease.' Confident Investing Starts Here:
Yahoo
22-05-2025
- Business
- Yahoo
Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal
Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company, for around $470 million, aiming to strengthen its research pipeline with a potential new Alzheimer's treatment. Under the agreement, Vigil shareholders will receive $8 per share, along with the possibility of an extra $2 per share through a contingent value right (CVR). This CVR depends on the progress of a drug Vigil is developing to treat Alzheimer's. If the CVR conditions are met, the total value of the deal could rise to approximately $600 million. The transaction is expected to be finalized in the third quarter and, according to Sanofi, it will not impact its financial guidance for 2025. Through this acquisition, Sanofi (NASDAQ:SNY) would gain access to VG-3927, an experimental oral therapy for Alzheimer's. The company had already invested $40 million in Vigil in June 2024, securing exclusive negotiation rights for the drug. However, Vigil's VGL101 monoclonal antibody program is not part of the deal and will be returned to Amgen, the U.S. pharmaceutical firm. Earlier this month, Sanofi (NASDAQ:SNY) also disclosed plans to invest at least $20 billion in U.S.-based manufacturing and research by 2030, through both its own facilities and collaborations with domestic partners. SNY has surged by nearly 10% since the start of 2025. While we acknowledge the potential of SNY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNY and that has 100x upside potential, check out our report about this cheapest AI stock. READ MORE: and Disclosure. None.
